GXO Logistics, Inc. Common Stock GXO 深 沪
已收盘 11-28 16:00:00 美东时间
50.74
+0.240
+0.48%
华盛通- 最 高50.87
- 今 开50.82
- 成交量 40.71万股
- 最 低 50.47
- 昨 收 50.50
- 总市值 57.84亿
- 52周最高 57.99
- 市盈率 静 45.36
- 换手率 0.00%
- 52周最低 30.46
- 委 比 42.86%
- 总股本 1.14亿
- 历史最高 105.92
- 量 比 0.36
- 振 幅 0.79%
- 历史最低 30.46
- 每 手 1
- 风险率 6.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GXO Logistics Receives EN 9120 Certification For Aerospace Quality Management Standard
GXO Logistics, Inc. (NYSE: GXO), the world's largest pure‑play contract logistics provider, today announced that its multi‑user facility in Dormagen has been certified to EN 9120 (AS/EN 9120), the aerospace quality
11-18 20:07
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
JP Morgan Maintains Overweight on GXO Logistics, Raises Price Target to $67
JP Morgan analyst Brian Ossenbeck maintains GXO Logistics (NYSE:GXO) with a Overweight and raises the price target from $66 to $67.
11-07 05:54
GXO Logistics Affirms FY2025 Adj EPS Guidance of $2.43-$2.63 vs $2.50 Est
GXO Logistics (NYSE:GXO) affirms FY2025 Adj EPS guidance from $2.43-$2.63 to $2.43-$2.63 vs $2.50 analyst estimate..
11-05 05:31
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
An Overview of XPO's Earnings
XPO (NYSE:XPO) is preparing to release its quarterly earnings on Thursday, 2025...
10-30 02:03
GXO Announces Organizational Changes to Accelerate Growth
GXO Logistics announces organizational changes to accelerate growth and streamline operations. Michael Jacobs is appointed President of Americas and Asia Pacific, bringing extensive supply chain experience. The company also simplifies its management structure, with Europe and UK regions reporting directly to CEO, and establishes a new Chief Operating Officer role to enhance global execution.
10-29 11:30
美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
10-09 10:51
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
